Regulatory Filing :

Japan

Mechanism of Action :

Taltirelin is a derivative of thyrotropin-releasing hormone (TRH). It would bind to TRH receptors which are widely distributed in the central nervous system, and improve ataxia in spinocerebellar degeneration by activating acetylcholine, dopamine, noradrenaline, and serotonin nervous systems. In addition, spinal reflex enhancing action, neurotrophic factor-like action, and local glucose metabolism promoting action are also considered to be involved in drug efficacy.

Indication :

Taltirelin is indicated for the improvement of ataxia in spinocerebellar degeneration.

Disclaimer
 

Please be reminded that some products listed above are still patented and can only be made available for R & D use as permitted under 35 USC ¶ 271 (e) (1); Article 69, Paragraph 1 of the Patent Act of Japan; Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004; or Article 69 (5) of the Patent Law of People’s Republic of China; or Article 60 of the Patent Act of Republic of China. We will not make, sell, offer for commercial sale or export the products listed above in/into regions or countries in which substance patents are still existing and we will not be responsible if the use of any of the above products infringes on any patent in your country.

Close